Senolytic MSC Therapy: Why Clearing Aged Cells First May Unlock Stem Cell Potential

A June 2026 study shows that senolytic preconditioning dramatically improves MSC efficacy by removing the SASP factors that suppress tissue repair. Plus: AAT-MSCs reverse diabetes via immune reprogramming, and a phase III MSC trial for meniscal repair reaches completion.

Lire la suite...

MSC Therapy for Lupus Nephritis: 120-Patient Study Shows 57% Renal Response at 12 Months

A 2026 real-world study followed 120 refractory lupus nephritis patients treated with UC-MSCs. Cumulative renal response reached 56.7% at 12 months with low relapse rates and zero severe adverse events. Here’s what clinicians need to know.

Lire la suite...

Stem Cell Therapy for Sports Injuries: What Weekend Warriors Need to Know

A 36-month clinical trial showed zero adverse events and 57% pain reduction when stem cells were injected into torn rotator cuffs. Here’s what weekend warriors and recreational athletes need to know about MSC therapy for sports injuries.

Lire la suite...

Intravenous UC-MSCs for Ischemic Stroke: What the MERIT Phase 1 Trial Tells Us

The MERIT phase 1 trial published in Cell Reports Medicine shows that intravenous UC-MSC therapy is safe in subacute ischemic stroke, with early NIHSS improvement signals. Here’s what clinicians need to know.

Lire la suite...
Haut